<!DOCTYPE doctype html>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <link href="./style.css" rel="stylesheet" type="text/css"/>
  
  <title id="pageTitle">
   # 099 Chemotherapy: Response and Survival Data, 2nd ed
  </title>

 </head>
 <body>

   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
       <div id="titleBarContainer">
        <h3>
         # 099 Chemotherapy: Response and Survival Data, 2nd ed
        </h3>
       </div>
       <!--/titleBarContainer -->
       <div blockinfo="Freeform CenterZone BlockID1" class="Freeform CenterZone BlockID1">
        
        <p>
         <br/>
         <b>
          Author(s):
         </b>
         David E Weissman MD and Charles F von Gunten MD
        </p>
        <p>
         <b>
          Background
         </b>
         Key data in the decision process regarding chemotherapy include the response rate, median duration of response, and median survival, along with toxicity and quality of life information (see
         <a href="./ff_014.htm" linktype="4" target="_blank">
          Fast Fact #14
         </a>
         ). The table below synthesizes data for several common cancers. The data were derived by reviewing standard oncology textbooks, along with a Medline search of recent relevant articles.
        </p>
        <p>
         <b>
          Comments on the Response and Survival Data
         </b>
        </p>
        <ul>
         <li>
          All data are for patients receiving chemotherapy for metastatic or locally advanced cancer (not receiving adjuvant or neoadjuvant chemotherapy).
         </li>
         <li>
          All data is for first-line, commercially available oral or IV chemotherapy or biological therapy (such as monoclonal antibodies).
         </li>
         <li>
          ‘Response Rate’ is defined as the percentage of complete and partial responders in a given trial, where ‘Partial Response’ = &gt; 50% reduction in measurable tumor for one month.
         </li>
         <li>
          Response is typically determined after 2 cycles of treatment (usually one cycle every 21-28 days); however, patients who progress after 1 cycle will generally continue progressing after two.
         </li>
         <li>
          The data reflect mid-point ranges derived from the available clinical trials; most of the data represent combination chemotherapy trials. Note: for certain cancers, the benefit of combination vs. single agent therapy is not proven (e.g. pancreas, biliary, liver).
         </li>
         <li>
          This information is not representative of all cancer patients. The data represent the ‘best case’ outcome, from a population of patients who were in good enough health to participate in a clinical trial (e.g. ambulatory, good functional status). Actual responses and response durations for a non-clinical trial population will likely be poorer.
         </li>
         <li>
          Data for biliary, pancreas, esophagus and liver come from many small trials (&lt; 50 patients), thus the upper end figures are likely to be overestimated.
         </li>
         <li>
          Second-line chemotherapy, following disease progression from first-line treatment, can be expected to have a lower response rate and shorter duration of response.
         </li>
         <li>
          Median survival data includes both responders and non-responders; patients who respond to chemotherapy typically live longer than those who do not.
         </li>
        </ul>
        <p>
        </p>
        <table align="center" border="1" cellpadding="3" cellspacing="0" height="241" style="width: 651px; height: 241px" width="651">
         <tbody>
          <tr>
           <td>
           </td>
           <td>
            <p style="text-align: center">
             <b>
              Response
             </b>
            </p>
            <p style="text-align: center">
             <b>
              Rate
             </b>
            </p>
           </td>
           <td>
            <p style="text-align: center">
             <b>
              Median Duration of
             </b>
            </p>
            <p style="text-align: center">
             <b>
              Response
             </b>
            </p>
           </td>
           <td style="text-align: center">
            <b>
             Median Survival
            </b>
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Breast
            </b>
           </td>
           <td style="text-align: center">
            25-55%
           </td>
           <td style="text-align: center">
            6-12 months
           </td>
           <td style="text-align: center">
            24-36 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Colon
            </b>
           </td>
           <td style="text-align: center">
            25-35%
           </td>
           <td style="text-align: center">
            6-8 months
           </td>
           <td style="text-align: center">
            12-18 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Esophagus
            </b>
           </td>
           <td style="text-align: center">
            30-50%
           </td>
           <td style="text-align: center">
            4-6 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Lung (Non-Small Cell)
            </b>
           </td>
           <td style="text-align: center">
            20-30%
           </td>
           <td style="text-align: center">
            4-6 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Stomach
            </b>
           </td>
           <td style="text-align: center">
            20-50%
           </td>
           <td style="text-align: center">
            4-6 months
           </td>
           <td style="text-align: center">
            6-12 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Melanoma
            </b>
           </td>
           <td style="text-align: center">
            15-25%
           </td>
           <td style="text-align: center">
            4-6 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Pancreas
            </b>
           </td>
           <td style="text-align: center">
            10-25%
           </td>
           <td style="text-align: center">
            3-5 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Liver (Hepatocellular)
            </b>
           </td>
           <td style="text-align: center">
            5-15%
           </td>
           <td style="text-align: center">
            2-4 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
          <tr>
           <td>
            <b>
             Biliary (Cholangio)
            </b>
           </td>
           <td style="text-align: center">
            15-25%
           </td>
           <td style="text-align: center">
            2-4 months
           </td>
           <td style="text-align: center">
            6-9 months
           </td>
          </tr>
         </tbody>
        </table>
        <p>
        </p>
        <p>
         <b>
          References
         </b>
        </p>
        <ol>
         <li>
          DeVita VT, et al, eds. Cancer: Principles and Practice of Oncology. 7th Edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2005.
         </li>
         <li>
          Kufe DW, et al, eds. Holland-Frei Cancer Medicine. 7th Edition. Hamilton, Ontario: BC Decker; 2006.
         </li>
        </ol>
        <p>
         <b>
          Fast Facts and Concepts
         </b>
         are edited by Drew A Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For more information write to:
         <a href="mailto:www.drosiell@mcw.edu?subject=EPERC%20Fast%20Facts%20and%20Concepts" linktype="5" target="_self">
          drosiell@mcw.edu
         </a>
         . More information, as well as the complete set of Fast Facts, are available at EPERC:
         <a href="http://www.eperc.mcw.edu" linktype="3" target="_blank">
          www.eperc.mcw.edu
         </a>
         .
        </p>
        <p>
         <b>
          Version History:
         </b>
         This Fast Fact was originally edited by David E Weissman MD. 2nd Edition was edited by Drew A Rosielle and published November 2007. Current version re-copy-edited April 2009.
        </p>
        

        <p>
         <b>
          ACGME Competencies:
         </b>
         Medical Knowledge, Patient Care
        </p>
        <p>
         <b>
          Keyword(s):
         </b>
         Non-Pain Symptoms and Syndromes; Prognosis
        </p>
       </div>
      </div>
      <!--/centerZone -->
      <div id="rightZone">
      </div>
      <!--/rightZone -->
     </div>
     <!--/contentContainer -->
    </div>
    <!-- /contentArea -->
    <!--/bottomContainer -->
   </div>
   <!--/mainBody -->
   

 </body>
</html>
